Moreover, several studies have explored the role of metabolites in the cardioprotective effects of SGLT2 inhibition, such as atrial fibrillation11 and cerebral small vessel disease,12 and found the mediating effects of the total concentration of lipoprotein particles and concentration of high-density lipoprotein particles on atrial fibrillation, 4-acetamidobutanoate on small vessel stroke, and the cholesterol to oleoyl-linoleoyl-glycerol ratio on the radial diffusivity of white matter. Here, SLC5A2 is linked to cerebral small vessel disease.